Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
12/2003
12/24/2003WO2003106425A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
12/24/2003WO2003106420A1 2,5-disubstituted 3-mercaptopentanoic acid
12/24/2003WO2003106416A2 Chemical process
12/24/2003WO2003106411A1 24-sulfoximine vitamin d3 compounds
12/24/2003WO2003106401A1 N-bridged selective androgen receptor modulators and methods of use thereof
12/24/2003WO2003106394A1 Preparations containing conjugated linoleic alcohol
12/24/2003WO2003106381A2 Human adam-10 inhibitors
12/24/2003WO2003105893A2 Probiotic therapies
12/24/2003WO2003105885A1 Novel method of screening
12/24/2003WO2003105881A1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne
12/24/2003WO2003105876A1 Horehound (marrubium vulgare) extract-based composition, production method thereof and uses of same
12/24/2003WO2003105869A1 Inhibitor of anticancer drug side effect
12/24/2003WO2003105867A1 Quaternised ammonium cyclodextrin compounds
12/24/2003WO2003105838A2 Metabolite
12/24/2003WO2003105824A1 Topical use of hydroxyeicosatetraenoic acid compounds to treat psoriasis
12/24/2003WO2003105821A1 A pharmaceutical composition comprising a corticosteroid and a nonsterodial anti-inflammatory agent
12/24/2003WO2003105816A1 Method of treating rosacea by topical application of a cyclohexane derivative
12/24/2003WO2003105776A2 ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
12/24/2003WO2003105771A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003WO2003091274A3 Use of alpha-s2 casein precursor-derived peptided
12/24/2003WO2003090662A3 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
12/24/2003WO2003086396A9 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
12/24/2003WO2003082807A3 Amino acids with affinity for the alpha-2-delta-protein
12/24/2003WO2003075015A3 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
12/24/2003WO2003072026A3 Method of reducing and treating uvb-induced immunosuppression
12/24/2003WO2003070914A3 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/24/2003WO2003070182A3 Sodium channel blockers
12/24/2003WO2003070180A3 Compositions and methods for delivery of skin cosmeceuticals
12/24/2003WO2003070153A3 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
12/24/2003WO2003066840A3 Pluripotent embryonic-like stem cells derived from teeth and uses thereof
12/24/2003WO2003066806A3 Therapeutic use of aziridino compounds
12/24/2003WO2003064685A3 Genetic polymorphisms in the preprotachykinin gene
12/24/2003WO2003063800A3 8-heteroaryl xanthine adenosine a2b receptor antagonists
12/24/2003WO2003062236A8 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
12/24/2003WO2003061653A9 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
12/24/2003WO2003053361A3 PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
12/24/2003WO2003040174A3 Substituted amino ketone compounds
12/24/2003WO2003038095A3 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
12/24/2003WO2003006491A3 Peptide-based compounds for targeting intergin receptors
12/24/2003WO2002102997A3 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
12/24/2003WO2002102990A8 Fibroblast growth factor and nucleic acid encoding same
12/24/2003WO2002060483A3 Perylenequinones for use as photosensitizers and sonosensitizers
12/24/2003WO2002046147A3 Perturbed membrane-binding compounds
12/24/2003WO2002018540A3 Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications
12/24/2003WO2001085193A8 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
12/24/2003CN1463177A Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds
12/24/2003CN1462632A Usage of internal use and external used medicine made from fleur-de-lis and its preparation method
12/24/2003CA2489870A1 Low molecular weight oversulfated polysaccharide
12/24/2003CA2489866A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
12/24/2003CA2489648A1 Chemical process
12/24/2003CA2489592A1 Inhibitor of anticancer drug side effect
12/24/2003CA2489466A1 Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
12/24/2003CA2489312A1 Modulation of activation of glucocorticoid receptors .beta.-breakdown products of glucocorticoids
12/24/2003CA2489182A1 N-bridged selective androgen receptor modulators and methods of use thereof
12/24/2003CA2489130A1 Preparations containing conjugated linoleic alcohol
12/24/2003CA2488708A1 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
12/24/2003CA2488606A1 2,5-disubstituted 3-mercaptopentanoic acid
12/24/2003CA2488117A1 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003CA2485346A1 Human adam-10 inhibitors
12/23/2003US6667341 Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters; anticancer agents, hemological disorders, and inherited metabolic disorders
12/23/2003US6667331 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
12/23/2003US6667318 LFA-1 antagonist compounds
12/23/2003US6667313 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
12/23/2003US6667300 Purinyl substituted quinazoline-4-one derivatives
12/23/2003US6667298 26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds
12/23/2003US6667028 Hair growth promoter
12/23/2003US6667026 Allergic contact dermatitis treatment and composition therefor
12/18/2003WO2003104807A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003WO2003104485A2 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003WO2003104443A2 Hair follicle mesenchymal stem cells and use thereof
12/18/2003WO2003104402A2 Non-polymeric hematopoietic cell clots for delivery of active agents
12/18/2003WO2003104260A2 Pharmaceutical formulation
12/18/2003WO2003104236A1 Calcitonin gene related peptide receptor antagonists
12/18/2003WO2003104230A1 Bicyclic pyrimidine derivatives
12/18/2003WO2003104226A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104225A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104223A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003WO2003104222A1 Bisindolyl-maleimid derivatives as kinase inhibitors
12/18/2003WO2003104219A1 Nf-kb inhibitors
12/18/2003WO2003104218A1 Nf-:b inhibitors
12/18/2003WO2003104205A1 Aryloximes
12/18/2003WO2003104204A1 Pyridazine derivatives
12/18/2003WO2003104203A1 Therapeutic molecules and methods-1
12/18/2003WO2003104197A1 Polymorphic form xvi of fexofenadine hydrochloride
12/18/2003WO2003104195A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003WO2003103725A1 Compositions and methods for the diagnosis and treatment of tumor
12/18/2003WO2003103705A1 Metalloproteinase inhibitors
12/18/2003WO2003103695A1 Novel therapeutic use of polypodium extracts
12/18/2003WO2003103691A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103684A1 Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
12/18/2003WO2003103682A1 Compositions for cancer therapy saponins or sapogenins
12/18/2003WO2003103671A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/18/2003WO2003103665A1 Antiallergic
12/18/2003WO2003103663A2 Substituted pyrrolines as kinase inhibitors
12/18/2003WO2003103661A1 SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
12/18/2003WO2003103624A1 Method and composition for improving sensory characteristics of semisolid predominantly anhydrous
12/18/2003WO2003103604A2 Gamma lactams as prostaglandin agonists and use thereof
12/18/2003WO2003103590A2 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003WO2003103585A2 Methods of treating angiogenesis, tumor growth, and metastasis
1 ... 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 ... 1065